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In 2018, Jefferson et al.[1] updated a Cochrane review first published 
in 2008, in which they assessed the effects of influenza vaccines in 
healthy children. Vaccination against influenza remains the best 
way to protect individuals from developing influenza, which is often 
common in countries with a temperate climate. Children, particularly 
those <5 years of age, although at high risk of serious complications 
of influenza, are yet to be a group for whom influenza vaccination 
is strongly recommended.[2] In South Africa (SA), from 2013 to 
2015, the estimated mean annual number of influenza-associated 
illness episodes was 10 737 847, of which 10 598 138 (98.7%) were 
mild, 128 173 (1.2%) were severe but non-fatal, and 11 536 (0.1%) 
resulted in death. Influenza-associated death rates of individuals in 
the population were high among children aged <1 year (80.3/100 000) 
and persons ≥65 years (137.9/100 000).[3,4] 
The economic burden of influenza is equally substantial. Currently, 
SA spends an estimated USD270.5 million each year to treat 
influenza-associated illness.[3] Economic loss due to absenteeism 
caused by influenza amounted to >USD200 million each year across 
all sectors.[5] Even though SA is one of the first 4 countries in Africa 
to have introduced the influenza vaccine to target risk groups, 
children <5 years of age are not prioritised for seasonal influenza 
vaccination by the National Department of Health.[2]
Objectives
Jefferson et al.[1] sought to determine the efficacy, effectiveness and 
safety of seasonal influenza vaccines in healthy children between 
2 and 16 years of age. Efficacy of the influenza vaccine was 
defined as a reduction in the number of laboratory-confirmed cases, 
while effectiveness was a reduction in influenza-like illness (ILI) 
symptomatic cases. 
Methods
Two types of vaccines, i.e. live attenuated influenza vaccines 
(LAIVs) or inactivated influenza vaccines (IIVs), were compared 
with a placebo or no vaccine. The authors of the review included 
41 randomised controlled trials (RCTs) with >200 000 children in 
studies conducted over single influenza seasons. The review also 
retained 21 cohort and 12 case control studies previously included 
in the last review. The studies from 1974 to 2016 were mainly 
from the USA, Western Europe, Russia and Bangladesh. Electronic 
databases, such as the Cochrane Central Register of Controlled 
Trials (CENTRAL), MEDLINE, Embase, World Health Organization 
(WHO) International Clinical Trials Registry Platform (ICTRP) and 
ClinicalTrials.gov, were comprehensively searched for published or 
unpublished studies. All the included studies were independently 
screened and assessed for risk of bias. Risk ratio (RR) and odds ratio 
(OR) were used to measure the benefits of the vaccines between the 
vaccinated group and comparison group. Data synthesis for LAIV 
and IIV was analysed separately and by grouping studies together, 
based on their study designs. Pooled estimates were assessed for 
heterogeneity by performing a sensitivity analysis. 
Results
The overall efficacy of LAIVs in reducing laboratory-confirmed 
influenza among healthy children aged 3 - 16 years was 78%, while 
effectiveness in reducing ILI was only 31%. In children aged 2 - 16 years, 
efficacy of inactivated influenza vaccines was 64% in reducing 
influenza and effectiveness was 28% in reducing ILI. Based on the 
risk difference of the disease reduction, 7 children vaccinated with 
LAIVs or 5 children vaccinated with IIVs are needed to prevent 1 case 
of laboratory-confirmed influenza. Similarly, 20 children vaccinated 
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
COCHRANE CORNER
Role of vaccines in preventing influenza in healthy 
children 
E Z Sambala,1 PhD; S Cooper,1,2 PhD; B-M Schmidt,1 PhD; S Walaza,3,4 PhD; C S Wiysonge,1,2,5 PhD
1 Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa
2 School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
3 Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases, National Health Laboratory Service,  
Johannesburg, South Africa 
4 School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa 
5 Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
Corresponding author: E Z Sambala (evanson_sambala@yahoo.com) 
The role of an influenza vaccine is to minimise illness and death. Vaccines provide good protection against influenza strains and 
significantly reduce time off work. However, the recommendation for use depends on the efficacy, effectiveness and safety of the vaccines. 
We highlight a Cochrane review that sought to determine the efficacy, effectiveness and safety of seasonal influenza vaccines in healthy 
children, and provide implications for practice for vaccination of children. The findings suggest that influenza vaccines play a key role in 
reducing serious morbidity and mortality among children. There were few data available to provide firm conclusions on adverse events. 
Vaccinating against influenza not only reduces its incidence among children, but also extends these benefits to the unvaccinated population, 
such as the elderly. In light of the many direct and indirect benefits of vaccinating children aged 2 - 16 years, there is a need to provide access 
to influenza vaccines to all eligible South African children. 
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with LAIVs or 12 children vaccinated with IIVs are needed to avoid 
1 case of ILI. There were few data available to provide firm conclusions 
on adverse events, hospitalisation and school and work absenteeism. 
Conclusions
LAIV and IIV are effective in reducing influenza and ILI in children 
aged 2 - 16 years. However, reduction estimates for both types of 
vaccines varied considerably among study populations, making it 
difficult to predict the precise size effects of the vaccine in other 
settings and for different seasons. 
Implications for practice 
Although the synthesised evidence was drawn from many studies 
conducted in populations outside Africa, the findings are very 
relevant to the SA context. LAIVs and IIVs provide significant 
protection against influenza in children aged 2 - 16 years. The 
WHO recommends IIVs in children >6 months old and LAIVs in 
individuals aged 2 - 49 years.[6] Vaccination against influenza does 
not only reduce its incidence among younger individuals, but also 
extends these benefits to the unvaccinated population.[7] 
Children have a high attack rate and play a significant role in 
influenza transmission in the household, schools and community 
owing to their prolonged virus shedding and tendency to mix more 
often with contacts of individuals. By targeting children, one could 
possibly reduce transmission to the elderly, who are at increased 
risk of severe outcomes due to influenza. As children respond better 
to vaccines than adults owing to their excellent immunological 
function, they are more likely to establish secondary effects over 
time, which are useful to stop the spread of the disease. Children’s 
protective benefits imply that the elderly are not directly exposed 
to influenza, thereby effectively enjoying protection offered by a 
vaccinated child. Furthermore, the working population enjoys this 
protection rendered by vaccinated children, as the latter are no 
longer vectors of transmission. The vaccination of children is an 
important strategy in preventing work absenteeism, which costs the 
SA government >ZAR3 billion yearly.[3] 
For adults, indirect benefits may be obtained by vaccinating only 
20 - 25% of children with a trivalent-LAIV, which subsequently results 
in secondary protection of 8 - 18% against medically attended acute 
respiratory illness.[8,9] Loeb et al.[7] suggest that if 61% of children 
and adolescents aged 3 - 15 years are immunised with the trivalent 
influenza vaccine, it will create a situation where the virus no longer 
circulates among unvaccinated persons. This corresponds to a study 
by Reichert et al.,[10] who vaccinated >80% of schoolchildren between 
1962 and 1987, resulting in a significant reduction in mortality in the 
elderly and adults. 
In light of the many direct and indirect benefits of vaccinating 
children aged 2 - 16 years, there is a need to provide access to 
influenza vaccines to all eligible SA children. 
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